Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | NAE1 | Q13564 | 1/20 | 0.36 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.36 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.36 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17065278 | 0.94 | KMT2A (0.40) | KMT2APOLBTDP1KDM4CRAB9A | |
| SCHEMBL28112266 | 0.85 | KMT2A (0.40) | KMT2APOLBTDP1P2RY14KDM4C | |
| SCHEMBL17489085 | 0.81 | P2RY14 (0.44) | KMT2APOLBTDP1P2RY14KDM4C | |
| SCHEMBL17438083 | 0.79 | SMN1; SMN2 (0.47) | KMT2APOLBTDP1P2RY14KDM4C | |
| SCHEMBL19902354 | 0.78 | RIPK1 (0.39) | KMT2APOLBTDP1KDM4CRAB9A | |
| SCHEMBL2827007 | 0.78 | POLB (0.37) | KMT2APOLBTDP1KDM4CNAE1 | |
| SCHEMBL31708636 | 0.77 | CNR2 (0.39) | KMT2APOLBTDP1KDM4CRAB9A | |
| SCHEMBL17452574 | 0.77 | KMT2A (0.38) | KMT2APOLBTDP1KDM4CNAE1 | |
| SCHEMBL17437913 | 0.77 | KMT2A (0.59) | KMT2APOLBTDP1KDM4CNAE1 | |
| SCHEMBL24914915 | 0.75 | KMT2A (0.44) | KMT2APOLBTDP1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237411-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-9856244-B2 | Dihydropyridinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170267666-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO | 2017-09-21 | — | — | US | disclosed |
| US-20170267666-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO | 2017-09-21 | — | — | US | disclosed |
| US-9701672-B2 | Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701672-B2 | Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170015653-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170015653-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-19 | — | — | US | disclosed |
| EP-3114121-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | Bristol-Myers Squibb Company (US) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015134701-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-11 | — | — | WO | disclosed |
| WO-2015134701-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015653-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | DGAT2, MGAT2, DGAT1 | KMT2A 300/4885POLB 2896/4885TDP1 3297/4885 |
| US-20170267666-A1 | DIHYDROPYRIDINONE MGAT2 INHIBITORS | DGAT2, DGAT1, MGAT2 | KMT2A 224/4885POLB 3290/4885TDP1 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.